Longeveron Q1 2023 Earnings Report $1.65 +0.05 (+3.13%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Longeveron EPS ResultsActual EPS-$2.20Consensus EPS -$1.90Beat/MissMissed by -$0.30One Year Ago EPSN/ALongeveron Revenue ResultsActual Revenue$0.28 millionExpected Revenue$0.30 millionBeat/MissMissed by -$20.00 thousandYoY Revenue GrowthN/ALongeveron Announcement DetailsQuarterQ1 2023Date5/12/2023TimeN/AConference Call ResourcesLGVN Earnings History We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Longeveron Earnings HeadlinesLongeveron to Present at Biotech Showcase 2025December 18 at 9:10 AM | globenewswire.comRoth MKM Initiates Coverage of Longeveron (LGVN) with Buy RecommendationDecember 6, 2024 | msn.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 21, 2024 | Crypto 101 Media (Ad)Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024December 2, 2024 | globenewswire.comLongeveron Buy Rating Affirmed: Promising Clinical Developments and Strong Financial PositionNovember 26, 2024 | markets.businessinsider.comLongeveron Inc. (LGVN) Latest Stock News & Headlines - Yahoo FinanceNovember 24, 2024 | finance.yahoo.comSee More Longeveron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Longeveron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longeveron and other key companies, straight to your email. Email Address About LongeveronLongeveron (NASDAQ:LGVN), a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.View Longeveron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
